Dr. Robert Califf says in an interview with CNBC that better regulation is needed to combat health misinformation that's costing Americans years of life.
Califf, a cardiologist, said he has "great hope for this class of drugs," noting it's one of a growing number of classes of medicines "that are dealing with the axis between our gut and our brain."
He noted he's looking forward to results from studies known as outcomes trials looking at whether the medicines lower the risk of heart disease and stroke when used by people who are obese but don't have diabetes. Results from Novo Nordisk's outcomes trial for Wegovy are expected this summer. Questions may remain about the longer-term safety of taking these medicines: Novo Nordisk's executivesCaliff said the U.S. could improve its data collection systems using electronic health records to track things like the long-term safety of these drugs.
Califf also noted it's possible the drugs will prove to be safer than hoped. He cited statins — for high cholesterol — and drugs for high blood pressure. He said the profile of those medicines "looks better and better over time."
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Mental Health Expert: How to Choose the Right Behavioral Health Provider foWith so many different types of providers and specialties, it's important to choose one who will help your child reach their best potential.
Leer más »
Mental health blogger: 'Paddling around Scotland is a delight'Mental health blogger Nick Ray continues his kayak trip around Scotland, despite a health scare.
Leer más »
Texas federal judge halts FDA approval of abortion pill mifepristone; Biden administration filing appealThe FDA approved mifepristone more than 20 years ago.
Leer más »
Abortion Pill Ruling Could Threaten Vaccines, Contraception, Advocates SayAbortion rights advocates and former FDA officials warned that a federal court decision on medication abortion puts all other FDA-approved drugs at risk.
Leer más »